Kewei Xu

Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer

ABSTRACT Resistance to second‐generation antiandrogens poses a major therapeutic challenge in castration‐resistant prostate cancer (CRPC). While ferroptosis evasion has been implicated in treatment failure, the key molecular determinants driving this evasive process are poorly un...

Evaluating global clinical trials and development trends of antibody-drug conjugates

Antibody-drug conjugates (ADCs) represent a breakthrough in tumor-targeted therapy, showing promise in both solid tumors and hematological malignancies. By 1 September 2025, more than 370 ADC candidates had entered clinical development, 17 unique products had received at least on...